Business Context and Reporting Period
Company: eXoZymes Inc. (Nasdaq: EXOZ)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: eXoZymes is a pre-revenue biotechnology company developing a synthetic biology platform for the scalable production of chemical molecules. The company operates as a single segment focused on research and commercialization of exozyme biosolutions. As of March 31, 2026, the company had 8,478,992 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,370,247) | $(1,856,421) |
| Net Loss Per Share (Basic & Diluted) | $(0.28) | $(0.22) |
| Operating Costs | $2,386,974 | $1,950,728 |
| Cash and Cash Equivalents (End of Period) | $1,444,562 | $8,511,477 |
| Net Cash Used in Operating Activities | $(1,524,441) | $(1,133,533) |
| Working Capital | $507,586 | $2,372,687 (Dec 31, 2025) |
| Total Assets | $4,018,841 | $5,971,517 (Dec 31, 2025) |
| Total Liabilities | $2,490,741 | $2,574,268 (Dec 31, 2025) |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by 27.7% (or $513,826) compared to Q1 2025, driven primarily by a 95.0% increase in Research and Development (R&D) costs.
- R&D Expense Surge: R&D costs rose from $575,016 in Q1 2025 to $1,121,008 in Q1 2026. Management attributes this to higher salaries, bonus accruals, stock-based compensation, and laboratory expenses, alongside a reduction in grant funding offsets.
- Compensation Costs: General and administrative compensation increased by 35.3% ($216,800) due to new hires not funded by grants.
- Professional Fees Decline: Professional fees decreased by 47.8% ($254,556) due to lower consulting, legal, and audit expenses.
- Cash Position: Cash and cash equivalents decreased by 52.5% ($1.59 million) from the beginning of the period, reflecting the operating cash burn.
- Grant Receivables: Grants receivable decreased by 41.5% ($214,496) due to the completion of certain grants and timing of drawdowns.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. Current working capital is insufficient to fund operations for a full twelve-month period. The company relies on securing additional financial support through equity/debt financing or achieving profitable operations.
- Proposed Offering: On April 10, 2026, the company announced a proposed public offering of approximately $15 million of common stock, underwritten by Public Venture, LLC (a subsidiary of its largest shareholder). A preliminary prospectus was filed on April 9, 2026. No definitive agreement has been signed.
- Grant Funding: The company received a $3 million share of a $9.2 million NSF grant in July 2025. Grant reimbursements from the Department of Energy (83.2%) and NIH (16.8%) remain critical to offsetting R&D costs.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting. While remediation is ongoing, disclosure controls were deemed not effective as of March 31, 2026.
- Risk Factors: Risks include potential U.S. tariff changes, government actions limiting research grants, supply chain disruptions, and the uncertainty of commercializing pre-revenue technology.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the proposed $15 million public offering and the likelihood of closing given current market conditions.
- Grant Sustainability: Assess the stability of government grant funding (DoE and NIH) which offsets a significant portion of R&D expenses.
- Internal Controls: Review the progress of remediation efforts regarding the material weaknesses in financial reporting controls.
- Burn Rate: Monitor the quarterly cash burn rate against the current cash balance of ~$1.44 million to determine immediate liquidity needs.
- Related Party Transactions: Note the outstanding payable of $13,406 to MDB Capital Holdings, LLC (a related party and largest shareholder).